AIM
MREO

Axiom Investment Management’s Mereo BioPharma MREO Stock Holding History

Axiom Investment Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Buy
+1
New – ﹤0.01% 386
2022
Q4 		– Sell
-1
Closed – – 286
2022
Q3 		$0 Buy
+1
New +$1 ﹤0.01% 439

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Axiom Investment Management's MREO Position: Q1 2026 in Review

Axiom Investment Management opened a new position in Mereo BioPharma (MREO) in Q1 2026: 1 share worth $0. The stake represents ﹤0.01% of the portfolio and ranks #386 among its holdings. This is a return to the name: Axiom Investment Management previously reported a position in MREO as recently as Q3 2022.

Axiom Investment Management first reported a position in MREO in Q3 2022 and has held it in 2 quarters since. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • Axiom Investment Management held 1 share of Mereo BioPharma worth $0 as of Q1 2026.
  • Mereo BioPharma was a new Axiom Investment Management position in Q1 2026.
  • Mereo BioPharma made up ﹤0.01% of Axiom Investment Management's portfolio in Q1 2026, its #386 holding.
  • Axiom Investment Management first reported a position in Mereo BioPharma in Q3 2022 and has held it in 2 quarters since.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Axiom Investment Management's 13F filing for Q1 2026, filed 26 May 2026.